

SNV's; Indels

AKT1, ALK, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO

CNV's

AKT1, ALK, AR, BRAF, CCND1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KIT, KRAS, MET, MYC, MYCN, PDGFRA, PIK3CA

Fusions

ABL1, AKT3, ALK, AXL, BRAF, EGFR, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1





Oncomine Focus



Hot spot screening of relevant, Druggable mutations, copy number changes and fusions for various Cancers



Analysing of 1000 variants across 52 genes for — cancers



ACMG/AMP guidelines-based reporting with drugs and target information



NGS based assay eliminate need of multiple technology FISH, IHC, Real time




High Sensitivity and Specificity



Identifies druggable targets in various cancers

List of key druggable and driver mutation genes in different cancer



Test Name	Test Code	Price	TAT
NextGen Oncomine Focus 52 Gene Panel	O0042	39500	4 Weeks

1.Bamba-Funck J. Fabre Et. Kambouchner M. Schischmandt (D. Performance Characteristics of Oncomine Focus Assay for Theranostic Analysis of Solid Tumors, A(21-Months) Real-Life Study, Diagnostics (Basel). 2023 Mar 113(\$5)337. doi: 10.3390/diagnostics10503937 PMID: 389003081 PMID: 159003081 PMID: 159003

For queries please write to us at oncomet@metropolisindia.com

